Health Condition 1: F209- Schizophrenia, unspecified
Conditions
Interventions
Intervention1: Paliperidone Prolonged-release Suspension for Injection, 175 mg: Administration
Frequency: Single dose, IM
Control Intervention1: Trevicta® Prolonged-release Suspension for Injection,
Sponsors
Mylan Laboratories Limited
Eligibility
Inclusion criteria
Inclusion criteria: Subject candidates must fulfill all of the following inclusion criteria to be eligible for participation in the study, unless otherwise specified: 1. Male or on-pregnant, non-lactating female subjects between 18 and 65 years of age (both inclusive) 2. Patients having a clinical diagnosis of schizophrenia as per DSM V criteria. 3. Patients without established tolerability and responsiveness to oral paliperidone/risperidone or injectable paliperidone, will be tested for tolerability of Paliperidone during screening 4. Subjects who are clinically stable with no hospitalizations for exacerbation of psychiatric symptoms 5. Weight: Each subject is required to weigh at least 50 kg (110 lbs) for men and 48 kg (106 lbs) for women and have a Body Mass Index (BMI) value less than or equal to 35.0 kg/m2 but greater than or equal to 18.0 kg/m2.
Exclusion criteria
Exclusion criteria: 1. Institutionalized subjects. 2. Subjects with history of alcohol or drug-dependence as per DSM-V criteria 3. Subjects with ingestion of any alcoholic beverage within the 24 hours 4. Subjects with ingestion of risperidone long acting injection 5. Subjects with depot injection or implant of any drug other than hormonal contraceptive or hormone replacement therapy 6. Subjects currently being treated with Clozapine, monoamine oxidase inhibitor (MAOI) antidepressants, electroconvulsive therapy 7. Use of any medication, herbal supplement, or vitamin known to induce or inhibit hepatic enzyme activity 8. Subjects with dementia related psychosis 9. Subjects with Clinical Global Impression - Severity of illness (CGI-S) score of 5 or more 10. Subjects with suicidal ideation 11. Subjects with a history of Neuroleptic Malignant Syndrome (NMS) 12. History of any significant cardiovascular, hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychological, genitourinary, musculoskeletal disease, uncontrolled metabolic diseases, clinically significant laboratory results or malignancies by the Principal Investigator or Medical Sub-Investigator. 13. Use of drugs that prolong the QTc interval, 14. Subjects with positive HIV, hepatitis B antigen, hepatitis C antibody, RPR or VDRL test 15. Subjects with positive urine drug screen 16. Subjects with history or presence of tardive dyskinesia, seizures idiopathic Parkinson’s disease, cognitive and motor impairment. 17. Subjects with donation or loss of blood or plasma 18. Subjects with participation in any interventional clinical study 19. Subjects with allergy or hypersensitivity to paliperidone, risperidone, other related products, or any inactive ingredients 20. Subjects has clinical signs and symptoms consistent with COVID-19 or had severe COVID-19
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the bioequivalence of Mylan’s Paliperidone Prolonged-release Suspension for Injection 175 mg of Mylan Laboratories Limited, India with Janssen-Cilag’s Trevicta 175 mg (equivalent to 273 mg Paliperidone Palmitate) after Single dose in subjects with schizophrenia.Timepoint: To evaluate the bioequivalence of Mylan’s Paliperidone Prolonged-release Suspension for Injection 175 mg of Mylan Laboratories Limited, India with Janssen-Cilag’s Trevicta Prolonged-release Suspension for Injection, 175 mg after single dose in subjects with schizophrenia. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the safety and tolerability of Mylan’s Paliperidone Prolonged-release Suspension for Injection, 175 mg throughout the study in subjects with schizophreniaTimepoint: Safety will be assessed throughout the study, i.e., from signing of ICF to end of study visit (Day 420) | — |
Countries
India
Contacts
Public ContactMr Maulik Patel
Cliantha Research Limited
Outcome results
None listed